Velicept Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Out of Business

  • Investors
  • 1

Velicept Therapeutics General Information

Description

Developer of drugs designed to transform the treatment of overactive bladder. The company's drugs are made using a novel compound which is a highly differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, enabling physicians to have drugs with the potential to improve patients' lives.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 640 Lee Road
  • Suite 119
  • Wayne, PA 19087
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Velicept Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Jul-2022 0000 Completed Out of Business
5. Debt - PPP 15-Apr-2020 0000 Completed Generating Revenue
4. Early Stage VC (Series B) 05-Nov-2019 00.00 0000 000.00 Completed Generating Revenue
3. Debt - General 01-Oct-2018 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 16-Jul-2018 $15.5M $42.8M 000.00 Completed Generating Revenue
1. Early Stage VC (Series B) 01-May-2017 $27.3M $27.3M 000.00 Completed Startup
To view Velicept Therapeutics’s complete valuation and funding history, request access »

Velicept Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.00
To view Velicept Therapeutics’s complete cap table history, request access »

Velicept Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs designed to transform the treatment of overactive bladder. The company's drugs are made using a novel
Drug Discovery
Wayne, PA
10 As of 2020
0000
00000000 00 0000

000000

it, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim a
0000 000000000
Irvine, CA
000 As of 0000
00000
0.000 0000-00-00
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Velicept Therapeutics Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Urovant Sciences Corporate Backed or Acquired Irvine, CA 000 00000 00000000000
You’re viewing 1 of 1 competitors. Get the full list »

Velicept Therapeutics Patents

Velicept Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3463307-A1 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Inactive 03-Jun-2016 0000000000
EP-3463312-A1 Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder Inactive 03-Jun-2016 0000000000
US-20170348288-A1 Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder Inactive 03-Jun-2016 0000000000
US-20170348263-A1 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Inactive 03-Jun-2016 0000000000 0
EP-3463307-A4 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Inactive 03-Jun-2016 A61K31/196 0
To view Velicept Therapeutics’s complete patent history, request access »

Velicept Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Velicept Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Becker Ventures PE/Buyout Minority 000 0000 000000 0
To view Velicept Therapeutics’s complete investors history, request access »

Velicept Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AltheRx Pharmaceuticals 15-Sep-2015 0000000000 Drug Discovery 0000000 0
To view Velicept Therapeutics’s complete acquisitions history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »